May 5, 2000

Daniel Tripodi, Ph.D.
The Sage Group, Inc.
245 Route 22 West, Suite 304
Bridgewater, NJ 08807

Re: Baxter International Inc.
Docket No. C-3726

Dear Dr. Tripodi:

This letter is to inform you that, pursuant to Paragraph II.C.8. of the above referenced order, the Commission has approved your March 23, 2000, request that the Commission extend the period for twelve (12) months, through May 8, 2001, during which NABI may continue to seek to obtain all necessary FDA approvals of its own to manufacture Baxter's Factor VIII Inhibitor Treatments.

By direction of the Commission.

Donald S. Clark
Secretary

cc: Michael Sennett, Esq.
Bell, Boyd & Lloyd
Three First National Plaza
70 West Madison Street, Suite 3300
Chicago, IL 60602-4207

Dr. Pinya Cohen, Vice President
Regulatory Affairs
NABI
5800 Park of Commerce Blvd., NW
Boca Raton, FL 33487